Accuracy of International Guidelines for Identifying Significant Fibrosis in Hepatitis B e Antigen–Negative Patients With Chronic Hepatitis  Faisal M. Sanai, Mohammed A. Babatin, Khalid I. Bzeizi, Fahad AlSohaibani, Waleed Al–Hamoudi, Khaled O. Alsaad, Hadeel Al Mana, Fayaz A. Handoo, Hamad Al–Ashgar, Hamdan AlGhamdi, Abeer Ibrahim, Abdulrahman Aljumah, Abduljaleel Alalwan, Ibrahim H. AlTraif, Hussa Al–Hussaini, Robert P. Myers, Ayman A. Abdo  Clinical Gastroenterology and Hepatology  Volume 11, Issue 11, Pages 1493-1499.e2 (November 2013) DOI: 10.1016/j.cgh.2013.05.038 Copyright © 2013 AGA Institute Terms and Conditions

Figure 1 Study algorithm showing application of AASLD, USPA, EASL, and APASL guidelines' thresholds of serum HBV DNA and ALT levels. Clinical Gastroenterology and Hepatology 2013 11, 1493-1499.e2DOI: (10.1016/j.cgh.2013.05.038) Copyright © 2013 AGA Institute Terms and Conditions

Figure 2 ROC curves of the 4 guidelines' criteria for identifying fibrosis ≥F2. In patients meeting AASLD criteria, sensitivity is 56.5% and specificity is 73.8% (AUROC, 0.59; 95% CI, 0.54–0.64); for USPA criteria, sensitivity is 45.7% and specificity is 82.4% (AUROC, 0.66; 95% CI, 0.58–0.73); for EASL criteria, sensitivity is 45.6% and specificity is 82.1% (AUROC, 0.66; 95% CI, 0.61–0.71); and for APASL criteria, sensitivity is 56.3% and specificity is 77.1% (AUROC, 0.64; 95% CI, 0.59–0.69). Clinical Gastroenterology and Hepatology 2013 11, 1493-1499.e2DOI: (10.1016/j.cgh.2013.05.038) Copyright © 2013 AGA Institute Terms and Conditions

Supplementary Figure 1 Presence of significant histology when HBeAg-negative patients were stratified on basis of the 4 guidelines' criteria. No significant differences were seen in relation to steatosis, ≥A2 necroinflammation, and ≥F2 fibrosis (P > .05 for all). Clinical Gastroenterology and Hepatology 2013 11, 1493-1499.e2DOI: (10.1016/j.cgh.2013.05.038) Copyright © 2013 AGA Institute Terms and Conditions

Supplementary Figure 2 ROC curve of the best compromise sensitivity-specificity of ALT (>1.09 × ULN) and HBV DNA (>3.91 log10 IU/mL) levels for identifying fibrosis score ≥F2. In patients meeting these criteria, sensitivity is 54.3% and specificity is 81.2% (AUROC, 0.73; 95% CI, 0.68–0.77; P < .0001). Clinical Gastroenterology and Hepatology 2013 11, 1493-1499.e2DOI: (10.1016/j.cgh.2013.05.038) Copyright © 2013 AGA Institute Terms and Conditions